SEATTLE, WA – Immunex Corporation (Nasdaq: IMNX) and Wyeth-Ayerst Laboratories, a division of American Home Products (NYSE: AHP) announced today that the U.S. Food and Drug Administration (FDA) has ...
Amgen’s arthritis blockbuster Enbrel already owns an undesirable spot on the list of 10 drugs eligible for the first round of Medicare pricing negotiations. Now, the company is fighting back against a ...
In 2024, the Colorado Prescription Drug Affordability Review Board declared Enbrel unaffordable, and last year it set an ...
When Amgen signed an outcomes-based reimbursement deal for its blockbuster rheumatoid arthritis drug Enbrel with Harvard Pilgrim Healthcare in 2017, it seemed like a strategy for preserving the market ...
By Jonathan Stempel July 1 (Reuters) - A federal judge on Wednesday blocked Colorado from capping the price of Amgen's ...
Phase 3 psoriatic arthritis data for ENBREL® (etanercept) announced at a national scientific meeting
SAN FRANCISCO, November 11, 2001 – Phase 3 results of ENBREL® (etanercept) studied in patients with psoriatic arthritis will be presented this week at the 65th Annual American College of Rheumatology ...
Sofusa is a drug delivery platform technology which delivers biologic therapies through the skin directly into the lymphatic system with potential to improve efficacy and safety and reduce the ...
WASHINGTON — Colorado is pioneering a new way for states to crack down on prescription drug costs. In a first-in-the-nation move, a state board voted to create a payment limit for a widely prescribed ...
I'm one of 47,000 Medicare recipients lucky enough to receive a drug that my old rheumatologist, who originally prescribed it for me, described as a miracle. When he was a young doctor, he told me, ...
Eight months after bowing to FDA pressure to pull the original spot, Amgen has launched a revamped television ad for Enbrel (etanercept) that it says better explains the product’s psoriasis indication ...
LONDON (Reuters) - A copy of the blockbuster biotech drug Enbrel was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results